Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 3.0 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Bristol Myers Squibb; Constellation Pharmaceuticals; Geron Corporation; Incyte Corporation; PharmaEssentia USA; Protagonist Therapeutics, Inc.; Sierra Oncology, Inc.; and Sumitomo Dainippon Pharma Oncology, Inc.
DIAGNOSIS AND TREATMENT OF MF AND PV: Where Are We and Where Are We Going?
Release Date: December 20, 2021
Expiration Date: December 20, 2022
Activity Overview
This virtual, on-demand webcast is specifically designed to meet the needs of busy clinicians who treat patients who have received a diagnosis of polycythemia vera (PV) or myelofibrosis (MF) by providing an update on optimal diagnosis, treatment selection, and emerging therapeutic options. These didactic presentations are placed into real-world context through discussion of 5 case scenarios spanning the disease continuum for PV and MF. These cases will help place recent findings and treatment recommendations into context for participants.
This educational activity is an archive of the virtual symposium held on December 10, 2021.
Acknowledgement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Bristol Myers Squibb; Constellation Pharmaceuticals; Geron Corporation; Incyte Corporation; PharmaEssentia USA; Protagonist Therapeutics, Inc.; Sierra Oncology, Inc.; and Sumitomo Dainippon Pharma Oncology, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine the impact of genetics, symptom burden, and risk stratification on therapy selection in MPNs
- Evaluate the clinical profiles of current and emerging therapeutic strategies in MPNs across lines of therapy
- Identify and manage disease-associated symptoms and treatment-related toxicities in patients with MPNs
- Translate updated clinical trial evidence and guidelines into personalized treatment plans for patients with MPNs to optimize care across the disease continuum
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
Chair
United Energy Resources, Inc. Professor of Medicine
Director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: Incyte Corporation; Roche; NS Pharma, Inc.; Celgene Corporation; Gilead Sciences, Inc.; Promedior, Inc.; CTI BioPharma Corp.; Genentech, Inc.; Blueprint Medicines; Novartis; Sierra Oncology, Inc.; PharmaEssentia; AstraZeneca; Italfarmaco; Protagonist Therapeutics, Inc. Consultant: Constellation Pharmaceuticals; Sierra Oncology, Inc.; Incyte Corporation; Novartis; Celgene Corporation; Bristol Myers Squibb.
Faculty
Assistant Member
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL
Disclosures: Grant/Research Support: Protagonist Therapeutics, Inc.; Sierra Oncology, Inc.; Prelude Therapeutics; Blueprint Medicines. Consultant: Protagonist Therapeutics, Inc.; PharmaEssentia; Blueprint Medicines; Incyte Corporation; CTI BioPharma Corp.; Constellation Pharmaceuticals.
Assistant Professor, Medicine-Hematology
University of Colorado Anschutz Medical Campus
Physicican Assistant
UCHealth Blood Disorders and Cell Therapies Center
Aurora, CO
Disclosures: Other: Advisory Boards: Bristol Myers Squibb and Protagonist Therapeutics
Associate Professor
Interim Chief, Division of Hematology and Oncology
Medical College of Wisconsin
Hematologist Oncologist
Cancer Center, Froedtert Hospital
Milwaukee, WI
Disclosures: Laura Michaelis, MD has no relevant financial relationships with ineligible companies.
Associate Professor of Medicine
University of Kansas Medical Center
Clinical Director of Ambulatory Hematology Clinics
The University of Kansas Cancer Center
Kansas City, KS
Disclosures: Speakers’ Bureau: Incyte Corporation; Agios Pharmaceuticals Inc.; Novartis.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
